drugset
drugset / Trial / NCT01320501

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

NCT01320501 ↗

Phase 4 Suspended 100 enrolled National Guard Health Affairs
NaSingle-groupOpen-labelTreatment

Summary

An open-label, prospective, single-arm, multi-center phase IV clinical trial of TarcevaTM as single agent

Timeline

Start
2009-10
Primary completion
2016-08
Completion
2016-08

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulty in enrolling patients”

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg Oral

Indications

non-small cell lung carcinoma